An overview of recombinant vaccines against viral, fungal, bacterial and parasitic diseases
DOI:
https://doi.org/10.63053/ijhes.104Keywords:
Infectious diseases, Listeria, Candida, Adenovirus, Leishmania, Recombinant vaccine, Disease control.Abstract
In the present era, particularly with the outbreak of infectious diseases including viral, fungal, parasitic, and bacterial infections, the need for designing and producing vaccines has become more critical than ever. Vaccination is one of the greatest public health achievements of the past century, protecting and improving the quality of life for people worldwide. Recombinant vaccines, produced using recombinant DNA technology, are discussed in this study. The microorganisms causing infections in humans, birds, and animals include adenovirus, infectious laryngotracheitis virus, human papillomavirus, Brucella and Listeria, Candida, Aspergillus, Cryptococcus, and Listeria. Vaccination is a highly effective strategy for controlling these types of diseases, making the acceleration of vaccine development essential for combating these diseases. Since one of the main factors contributing to the increased frequency and severity of diseases is the lack of cellular or humoral immunity, vaccine strategies must be safe and effective in hosts with both healthy and compromised immune systems. Advances in proteomics and systems biology have facilitated the development of several proposed vaccines, particularly as these vaccines enable the localization of proteins and the description of their changes, functions, and interactions.
References
• Aliramaei Reza Mohammad , Khorasgani Rabbani Mohammad, Rezaei M. (2020)Recombinant Lactococcus, a New Approach to Oral Vaccines. Volume 23, Issue 6 .doi: 10.32598/jams.23.6.5030.3
• Abdelaziz, K., Helmy, Y. A., Yitbarek, A., Hodgins, D. C., Sharafeldin, T. A., & Selim, M. S. (2024). Advances in Poultry Vaccines: Leveraging Biotechnology for Improving Vaccine Development, Stability, and Delivery. Vaccines, 12(2), 134.
• Adilson José da Silva , Teresa Cristina Zangirolami , Maria Teresa Marques Novo-Mansur , Roberto de Campos Giordano , Elizabeth Angélica Leme Martins.(2014). Live bacterial vaccine vectors: An overview. Brazilian Journal of Microbiology 45, 4, 1117-1129. ISSN 1678-4405
• B. R. Da Silva, L., P. Taborda, C., & D. Nosanchuk, J. (2020). Advances in Fungal Peptide Vaccines. Journal of Fungi, 6(3), 119. doi:10.3390/jof6030119
• Cassone, A., & Casadevall, A. (2012). Recent progress in vaccines against fungal diseases. Current Opinion in Microbiology, 15(4), 427–433. doi:10.1016/j.mib.2012.04.004
• 10.1016/j.mib.2012.04.004
• Chakraborty, R., & Parvez, S. (2020). COVID-19: An overview of the current pharmacological interventions, vaccines, and clinical trials. Biochemical pharmacology, 180, 114184.
• Cox, M. M. (2021). Innovations in the insect cell expression system for industrial recombinant vaccine antigen production. Vaccines, 9(12), 1504.
• Ebenig, A., Lange, M. V., & Mühlebach, M. D. (2022). Versatility of live-attenuated measles viruses as platform technology for recombinant vaccines. npj Vaccines, 7(1), 119.
• Eusébio, D., Neves, A. R., Costa, D., Biswas, S., Alves, G., Cui, Z., & Sousa, Â. (2021). Methods to improve the immunogenicity of plasmid DNA vaccines. Drug Discovery Today, 26(11), 2575-2592.
• Garedaghi Y.(2024). The Role of Vaccines in the Prevention of Parasitic Diseases in Humans and Animals. VSOHJ
• Gary, E. N., & Weiner, D. B. (2020). DNA vaccines: prime time is now. Current Opinion in Immunology, 65, 21-27.
• Hein, R., Koopman, R., García, M., Armour, N., Dunn, J. R., Barbosa, T., & Martinez, A. (2021). Review of poultry recombinant vector vaccines. Avian diseases, 65(3), 438-452.
• Hederman, A. P., & Ackerman, M. E. (2023). Leveraging deep learning to improve vaccine design. Trends in Immunology.
• Jaydari A, Nazifi N, Forouharmehr A. Computational design ofa novel multi-epitope vaccine against Coxiella burnetii. Human Immunology. 2020;81(10-11):596-605
• Jonathan Temte, M. (2020). Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults. Lancet.
• Lim, M., Badruddoza, A. Z. M., Firdous, J., Azad, M., Mannan, A., Al-Hilal, T. A., ... & Islam, M. A. (2020). Engineered nanodelivery systems to improve DNA vaccine technologies. Pharmaceutics, 12(1), 30.
• Lundstrom, K. (2021). Viral vectors for COVID-19 vaccine development. Viruses, 13(2), 317.
• McCann, N., O’Connor, D., Lambe, T., & Pollard, A. J. (2022). Viral vector vaccines. Current Opinion in Immunology, 77, 102210.
• Nazifi N.2024. Introducing and Bioinformatic Evaluation of a Chimeric and Effective Immunogen Construct for Designing a Recombinant Vaccine against Brucellosis. Bi-quarterly Journal of Animal health and infectious diseases Volume 1, Number 1
• Nisbet, A. J., McNeilly, T. N., Wildblood, L. A., Morrison, A. A., Bartley, D. J., Bartley, Y., … Matthews, J. B. (2013). Successful immunization against a parasitic nematode by vaccination with recombinant proteins. Vaccine, 31(37), 4017–4023. https://doi.org/10.1016/j.vaccine.2013.05.026
• Oliveira, L. V. N., Wang, R., Specht, C. A., & Levitz, S. M. (2021). Vaccines for human fungal diseases: close but still a long way to go. Npj Vaccines, 6(1). doi:10.1038/s41541-021-00294-8
• Pardi, N., Hogan, M. J., & Weissman, D. (2020). Recent advances in mRNA vaccine technology. Current opinion in immunology, 65, 14-20.
• Rezaei, T., Davoudian, E., Khalili, S., Amini, M., Hejazi, M., de la Guardia, M., & Mokhtarzadeh, A. (2021). Strategies in DNA vaccine for melanoma cancer. Pigment cell & melanoma research, 34(5), 869-891.
• Romano’, L., & Zanetti, A. R. (2022). Hepatitis B vaccination: A historical overview with a focus on the Italian achievements. Viruses, 14(7), 1515.
• Sanders, R. W., & Moore, J. P. (2021). Virus vaccines: proteins prefer prolines. Cell Host & Microbe, 29(3), 327-333.
• Santos, E., & Levitz, S. M. (2014). Fungal Vaccines and Immunotherapeutics. Cold Spring Harbor Perspectives in Medicine, 4(11), a019711–a019711. doi:10.1101/cshperspect.a019711
• Ura, T., Okuda, K., & Shimada, M. (2014). Developments in viral vector-based vaccines. Vaccines, 2(3), 624-641.
• Veysel Kayser & Iqbal Ramzan (2021) Vaccines and vaccination: history and emerging issues, Human Vaccines & Immunotherapeutics, 17:12, 5255-5268, DOI: 10.1080/21645515.2021.1977057
• Wang, Y., Li, J., Hu, Y., Liang, Q., Wei, M., & Zhu, F. (2017). Ebola vaccines in clinical trial: the promising candidates. Human vaccines & immunotherapeutics, 13(1), 153-168.
• Wagari, A. (2021). A review on infectious bursal disease in poultry. Health Econ. Outcome Res. Open Access, 7(2), 167.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Authors
This work is licensed under a Creative Commons Attribution 4.0 International License.
The journal is licensed under a Attribution 4.0 International (CC BY 4.0).
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution - You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions - You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
